Investments to keep 3.5 million people living with HIV on antiretroviral drugs provided by programs co-financed through the Global Fund to Fight AIDS, Tuberculosis and Malaria through 2020 will cost an estimated $14.2 billion, but “the financial savings would amount to between $12 billion and $34 billion,” according to a study published in the journal PLoS One, Sarah Boseley reports in her “Global Health Blog” in the Guardian (10/5).
“For the Bill & Melinda Gates Foundation, the Global Fund [to Fight AIDS, Tuberculosis and Malaria] is an invaluable partner, and the progress they have achieved is bringing us closer than ever to the reality of global health equity,” Joe Cerrell, director of the Gates Foundation’s European office, writes in an AlertNet opinion piece, adding, “Every day, programs supported by the Global Fund save at least 4,400 lives.”
Based on a report released last week by a high-level independent review panel on fiduciary controls and oversight mechanisms at the Global Fund to Fight AIDS, Tuberculosis and Malaria, “[t]he changes needed at the Fund are clearly substantial,” according to a Lancet editorial. “However, as the report notes, there is ‘nothing that cannot be fixed by appropriate reform.’ Whether governments in this era of austerity will stick by the Fund as it evolves is now a major concern. But there are good reasons for donors to keep funding the Global Fund,” the editorial states.
Global Fund Board Supports Recommendations Of Independent Review Panel, Will Implement 'Wide-Reaching Reforms'
“The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria approved an action plan Monday in response to recommendations made recently by the High-Level Independent Review Panel on Fiduciary Controls and Oversight Mechanism (HLP),” the Center for Global Health Policy’s “Science Speaks” blog reports, adding, “The board stated that it accepts the underlying analysis made by the panel and that it ‘presents a compelling case for a rapid and urgent transformation of the Global Fund.'”
The Global Fund to Fight AIDS, Tuberculosis and Malaria, “[a]long with our partners, both donors and implementers, [is] changing the story of scores of nations that were once devastated by three killer diseases — diseases which seemed invincible,” Global Fund Executive Director Michel Kazatchkine writes in a Huffington Post opinion piece, adding “we are now saving more than one million lives every year.”
In this entry in the Huffington Post’s “Impact” blog, Kolleen Bouchane, director of ACTION, an international partnership of advocates working to mobilize resources to treat and prevent the spread of tuberculosis (TB), examines the need for improved TB vaccines and diagnostics in order to curb the spread of multidrug-resistant TB, especially among children, and highlights ACTION’s new report (.pdf), “Children and Tuberculosis: Exposing a Hidden Epidemic,” which she says “exposes the link between TB and orphaned and vulnerable children, malnourished children or children living with HIV.”
In the second in a series of interviews with staff members of the Office of the U.S. Global AIDS Coordinator (OGAC), which is responsible for PEPFAR, the Center for Global Health Policy’s “Science Speaks” blog speaks with Winnie Roberts, director of multilateral diplomacy at OGAC. Roberts discusses negotiations surrounding the…
After a six-month review of the financial systems at the Global Fund to Fight AIDS, Tuberculosis and Malaria, a seven-member independent panel “recommended a substantial overhaul Monday in the grant organization’s practices,” the Wall Street Journal reports. The panel, led by former U.S. Secretary of Health and Human Services Michael Leavitt and former Botswana President Festus Mogae, “said in a report the fund must improve risk management, simplify grant application processes, and place greater emphasis on results,” according to the newspaper.
In this article in The American, a journal of the American Enterprise Institute for Public Policy Research, Roger Bate, the Legatum Fellow at the American Enterprise Institute, and Richard Tren, director of Africa Fighting Malaria, write that the Global Fund to Fight AIDS, Tuberculosis, and Malaria “launched a $225 million facility that offers subsidized malaria drugs …provid[ing] subsidies so that shops can sell relatively expensive drugs at low cost, thereby using the reach and power of markets to save lives,” they write, adding that the mechanism “is perverting the market for malaria drugs and could do more harm than good.” The authors call on Congress to examine the subsidy system, writing, “The United States is not funding the subsidy, but the subsidy is harming programs the United States is supporting. Understanding and then stopping wasteful spending decisions would save money and lives” (9/8).
“Burundian NGOs say at least 20 people have died” as a result of a “months-long shortage” of antiretroviral drugs (ARVs), although “Ministry of Health officials could not be reached to confirm the number of people affected,” PlusNews reports. “More than 60,000 Burundians need HIV treatment, but only about 25,000 have access to ARVs,” according to the news agency, which adds, “The shortage has been blamed on dwindling donor funds and a disorganized health ministry.”